Preclinical News and Research

RSS

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

7 Aug 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014.

7 Aug 2014

RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

Rett Syndrome Association of Massachusetts and Rettsyndrome.org are thrilled to announce today their renewed commitment to work together to defeat Rett syndrome. A generous $150,000 donation from RSAM will support a Rettsyndrome.org approved grant to Dr. Michela Fagiolini's project at the Boston Children's Hospital: "Assessing NMDA receptor (NMDAr) modulators to ameliorate cortical regression in Rett syndrome".

7 Aug 2014

Induced immunorejection may eliminate tumors post-cell transplantation

Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation.

7 Aug 2014

Repurposed drug used to treat ovarian cancer gives positive results

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase I clinical trial at The University of Kansas Cancer Center.

5 Aug 2014

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

UC San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients.

5 Aug 2014

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Despite improved therapy, only one out of every two adult patients survive acute myeloid leukaemia (AML). The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years. It is assumed that leukaemic stem cells, which cannot be completely eliminated during treatment, are the origin of relapse.

4 Aug 2014

Scientists unravel neural circuit that could play important role in autism

The insular cortex is an integral "hub", combining sensory, emotional and cognitive content. Not surprisingly, alterations in insular structure and function have been reported in many psychiatric disorders, such as anxiety disorders, depression, addiction and autism spectrum disorders (ASD).

1 Aug 2014

ChromaDex to provide Murdoch Childrens Research Institute with NR ingredient for research use

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia.

31 Jul 2014

Research findings suggest new therapeutic strategy for intracerebral hemorrhage

Intracerebral hemorrhage is a type of stroke that affects two million people worldwide each year. Despite its seriousness, no effective treatment has yet been developed. But if a recent study in the journal Nanomedicine is right, good news for doctors and patients might one day arrive in a very small package: namely, a "peptide nanofiber scaffold."

31 Jul 2014

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers.

28 Jul 2014

Xybion to host first annual Global User Group Conference in Philadelphia, Pennsylvania

Xybion Corporation, the leading provider of software, services and consulting for global corporations operating in highly regulated industries, announced today that the company will host its first annual Global User Group Conference, Xybion International Exchange, on October 21-23, 2014 in historic Philadelphia, Pennsylvania at the Sheraton Society Hill Hotel.

26 Jul 2014

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.

26 Jul 2014

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown.

26 Jul 2014

UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.

25 Jul 2014

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong.

25 Jul 2014

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.

25 Jul 2014

Preclinical News and Research

BioSpecifics Technologies total revenue for second quarter decreases by 19%

TAXIS acquires novel antimicrobial drug candidates from Biota

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Celsion announces financial results for second quarter ended 2014

RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

Induced immunorejection may eliminate tumors post-cell transplantation

Repurposed drug used to treat ovarian cancer gives positive results

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Scientists unravel neural circuit that could play important role in autism

ChromaDex to provide Murdoch Childrens Research Institute with NR ingredient for research use

Research findings suggest new therapeutic strategy for intracerebral hemorrhage

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Xybion to host first annual Global User Group Conference in Philadelphia, Pennsylvania

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

Researchers working to develop new drugs for treating chronic inflammatory diseases

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics